AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29501366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin 100 mg/m2 on days 1, 22, and 43 for three cycles concurrently with intensity-modulated radiotherapy
Number of subjects: 402
Study 29501366 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 on days 1, 22, and 43 for three cycles concurrently with intensity-modulated radiotherapy
Number of subjects: 402
Study 29501366 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 402
Study 29501366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Number of subjects: 402
Study 28753943 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-caffeine green tea (LCGT)
Number of subjects: 20
Study 28753943 — intervention group
Group type: COMPARATOR
Intervention: Standard green tea (SGT)
Number of subjects: 20
Study 26201996 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1.5% dexamethasone γ‐cyclodextrin nanoparticle eye drops (DexNP)
Number of subjects: 22
Study 26201996 — intervention group
Group type: COMPARATOR
Intervention: Posterior subtenon injection of 20 mg triamcinolone acetonide
Number of subjects: 22
Study 23902884 — intervention group
Group type: EXPERIMENTAL
Intervention: BBAVF
Number of subjects: 61
Study 23902884 — intervention group
Group type: COMPARATOR
Intervention: AVG
Number of subjects: 61
Study 20626389 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin 3.9 mg/day
Number of subjects: 96
Study 20626389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 18942245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique
Number of subjects: 100
Study 18942245 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-localized technique
Number of subjects: 100
Study 18942245 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 100
Study 16507192 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 2.5 minimum alveolar concentration for 15 min
Number of subjects: 40
Study 16507192 — intervention group
Group type: COMPARATOR
Intervention: Control group (isoflurane-free cardiopulmonary bypass)
Number of subjects: 40
Study 15255620 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 120
Study 15255620 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril and Losartan (A.C.E. inhibitors and A.II.R. antagonists)
Number of subjects: 120
Study 11103560 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion lesson modules implemented in the intervention school between T1 and T2 (12 months)
Number of subjects: 0
Study 11103560 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion lesson modules
Number of subjects: 0
Study 11103560 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion activities
Number of subjects: 0
Study 11103560 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in longitudinal study
Number of subjects: 0
Study 9132327 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma endothelin-1 (ET-1) levels in patients with BD
Number of subjects: 27
Study 9132327 — intervention group
Group type: COMPARATOR
Intervention: Plasma endothelin-1 (ET-1) levels in healthy controls
Number of subjects: 27
Study 7911639 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide administration
Number of subjects: 12
Study 3949595 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive subjects
Number of subjects: 30
Study 3949595 — intervention group
Group type: COMPARATOR
Intervention: Non-depressive psychiatric subjects
Number of subjects: 30
Study 3949595 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects considered on the same continuum of depression
Number of subjects: 30
Study 29465495 — intervention group
Group type: COMPARATOR
Intervention: Supervised treadmill exercise
Number of subjects: 1547
Study 29465495 — intervention group
Group type: COMPARATOR
Intervention: Home-based walking exercise interventions incorporating behavioral change techniques
Number of subjects: 1547
Study 29465495 — intervention group
Group type: COMPARATOR
Intervention: Home-based walking exercise
Number of subjects: 1547
Study 29465495 — intervention group
Group type: COMPARATOR
Intervention: Upper and lower extremity ergometry
Number of subjects: 1547
Study 29465495 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treadmill exercise (12 weeks, 36 sessions)
Number of subjects: 1547
Study 26510709 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter-tasting phenylalanine-free l-amino acid exposure
Number of subjects: 35
Study 26510709 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children), N=35
Number of subjects: 35
Study 25492853 — intervention group
Group type: EXPERIMENTAL
Intervention: Active interferential current + Pilates (n=74)
Number of subjects: 148
Study 25492853 — intervention group
Group type: COMPARATOR
Intervention: Sham interferential current + Pilates (n=74)
Number of subjects: 148
Study 23075413 — intervention group
Group type: EXPERIMENTAL
Intervention: Erzhi Tiangui Granule (ETG)
Number of subjects: 66
Study 23075413 — intervention group
Group type: COMPARATOR
Intervention: Placebo granules
Number of subjects: 66
Study 18607714 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing about traumatic experiences
Number of subjects: 37
Study 18607714 — intervention group
Group type: COMPARATOR
Intervention: Expressive writing about trivial topics
Number of subjects: 37
Study 18607714 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (both groups)
Number of subjects: 37
Study 18067973 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT) plus pharmacotherapy
Number of subjects: 45
Study 18067973 — intervention group
Group type: COMPARATOR
Intervention: Clinical Management (CM)
Number of subjects: 45
Study 18067973 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 45
Study 16884957 — intervention group
Group type: EXPERIMENTAL
Intervention: Liaison (LS) schools
Number of subjects: 10
Study 16884957 — intervention group
Group type: EXPERIMENTAL
Intervention: Champion (CS) schools
Number of subjects: 10
Study 16884957 — intervention group
Group type: COMPARATOR
Intervention: Usual Practice (UP) schools
Number of subjects: 10
Study 12538507 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 12538507 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxifene
Number of subjects: 0
Study 12538507 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 0
Study 12538507 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hydroxyandrostenedione (aromatase inhibitor)
Number of subjects: 0
Study 12538507 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 10800604 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial tear ointment applied to one eye
Number of subjects: 50
Study 10800604 — intervention group
Group type: COMPARATOR
Intervention: Passive closure of the eyelid (control eye)
Number of subjects: 50
Study 8645677 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (10 mg lozenges, four times daily for 14 days)
Number of subjects: 73
Study 8645677 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (50 mg daily for 7 days)
Number of subjects: 73
Study 1524175 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine, mean dose 3.6 micrograms/kg (n = 28)
Number of subjects: 58
Study 1524175 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam, 0.2 mg/kg (n = 30)
Number of subjects: 58
Study 2996991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low residue diet
Number of subjects: 70
Study 2996991 — intervention group
Group type: COMPARATOR
Intervention: Normal Italian diet
Number of subjects: 70
Study 30992220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal administration of human umbilical cord blood-derived mesenchymal stromal cells
Number of subjects: 12
Study 29317229 — intervention group
Group type: EXPERIMENTAL
Intervention: Music for pain reduction
Number of subjects: 0
Study 29317229 — intervention group
Group type: COMPARATOR
Intervention: Provider assessment
Number of subjects: 0
Study 29317229 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous abortion
Number of subjects: 0
Study 29317229 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intrauterine device insertion
Number of subjects: 0
Study 26992129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy plus Amitriptyline
Number of subjects: 135
Study 26992129 — intervention group
Group type: COMPARATOR
Intervention: Headache Education plus Amitriptyline
Number of subjects: 135
Study 24014167 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Matters (YM) bullying prevention trial
Number of subjects: 1077
Study 24014167 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1077
Study 24014167 — intervention group
Group type: EXPERIMENTAL
Intervention: YM group
Number of subjects: 1077
Study 22476387 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar 40 mg coadministered with warfarin 25 mg (Day 7) after multiple doses of vorapaxar 2.5 mg/day on Days 1-6
Number of subjects: 12
Study 22476387 — intervention group
Group type: COMPARATOR
Intervention: Warfarin 25 mg (Day 1)
Number of subjects: 12
Study 20127832 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive SEBST
Number of subjects: 597
Study 20127832 — intervention group
Group type: COMPARATOR
Intervention: Negative SEBST
Number of subjects: 597
Study 20127832 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic measures (VLPP, MUCP)
Number of subjects: 597
Study 17988199 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐T4 (Levothyroxine) treatment, N=20
Number of subjects: 37
Study 17988199 — intervention group
Group type: COMPARATOR
Intervention: Untreated group, N=17
Number of subjects: 37
Study 16685066 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus rhamnosus LC705 and Propionibacterium freudenreichii subsp. shermanii strains, 2 times/d for 5 weeks)
Number of subjects: 90
Study 16685066 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 90
Study 12842681 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg/kg intravenous bolus given 5 minutes before retrobulbar anesthesia
Number of subjects: 120
Study 12842681 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 120
Study 10915749 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa‐2b and placebo
Number of subjects: 1744
Study 10915749 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination interferon alfa‐2b and ribavirin
Number of subjects: 1744
Study 8840373 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMX (oral)
Number of subjects: 9
Study 8840373 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMX (IV)
Number of subjects: 9
Study 1738570 — intervention group
Group type: EXPERIMENTAL
Intervention: s‐CT (200 IU infusion)
Number of subjects: 21
Study 1738570 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 21
Study 6438935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 0.2 mg nifedipine and 10 mg sublingual nifedipine (group I)
Number of subjects: 28
Study 6438935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 0.4 mg 3‐N‐morpholinosyndnonimine (SIN‐1) (group II)
Number of subjects: 28
Study 31939365 — intervention group
Group type: EXPERIMENTAL
Intervention: CollaCote® membrane
Number of subjects: 20
Study 31939365 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF membrane
Number of subjects: 20
Study 25420063 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-purchase intervention (signage)
Number of subjects: 128
Study 23412170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular PRP injection
Number of subjects: 65
Study 21226958 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (≥ 900 kcal/wk)
Number of subjects: 50
Study 18299491 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (2.5 mg/d)
Number of subjects: 16608
Study 18299491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study 18299491 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens plus medroxyprogesterone acetate
Number of subjects: 16608
Study 18299491 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens plus medroxyprogesterone acetate after discontinuation
Number of subjects: 16608
Study 16565035 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy training
Number of subjects: 113
Study 16565035 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy as usual
Number of subjects: 113
Study 14525822 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% amethocaine
Number of subjects: 51
Study 14525822 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ketorolac
Number of subjects: 51
Study 14525822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 51
Study 10898674 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg orally every 24 hours for 2 days prior to surgery, followed by 500 mg as an hour-long intravenous infusion on the day of surgery.
Number of subjects: 0
Study 8606269 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced ventricular arrhythmias in group A (30 patients)
Number of subjects: 60
Study 8606269 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise SPECT in group A (30 patients)
Number of subjects: 60
Study 8606269 — intervention group
Group type: COMPARATOR
Intervention: Postexercise SPECT in group B (30 patients)
Number of subjects: 60
Study 8606269 — intervention group
Group type: EXPERIMENTAL
Intervention: Uptake of F-18 fluorodeoxyglucose in group A (13 patients)
Number of subjects: 60
Study 8606269 — intervention group
Group type: COMPARATOR
Intervention: Uptake of F-18 fluorodeoxyglucose in group B (13 patients)
Number of subjects: 60
Study 1457484 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol-300
Number of subjects: 27
Study 1457484 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol-370
Number of subjects: 27
Study 6487515 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation 15 Grays in 10 fractions in 2 weeks
Number of subjects: 120
Study 6487515 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant radiation)
Number of subjects: 120
Study 30040719 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-high intensity aerobic exercise for 16 weeks
Number of subjects: 55
Study 30040719 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 55
Study 30040719 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from IG and CG
Number of subjects: 55
Study 27471785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 2400
Study 27471785 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 2400
Study 25028522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin application
Number of subjects: 0
Study 25028522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23408502 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (ADF plus endurance exercise)
Number of subjects: 64
Study 23408502 — intervention group
Group type: EXPERIMENTAL
Intervention: ADF
Number of subjects: 64
Study 23408502 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 64
Study 23408502 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study 20529449 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of autologous bone marrow stem cells (ABMSC) concentrate in group I (n = 42)
Number of subjects: 96
Study 20529449 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care in group II (n = 54, control)
Number of subjects: 96
Study 20529449 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of ABMSC in group I
Number of subjects: 96
Study 20529449 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who failed ABMSC therapy
Number of subjects: 96
Study 20529449 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMSC therapy
Number of subjects: 96
Study 19017387 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 146
Study 19017387 — intervention group
Group type: COMPARATOR
Intervention: dihydroartemisinin-piperaquine (DP)
Number of subjects: 146
Study 16626379 — intervention group
Group type: EXPERIMENTAL
Intervention: Behind-the-Knee test (BTK test)
Number of subjects: 35
Study 12620717 — intervention group
Group type: EXPERIMENTAL
Intervention: 2:1 coordination pattern training (1L:2R)
Number of subjects: 16
Study 12620717 — intervention group
Group type: EXPERIMENTAL
Intervention: 2:1 coordination pattern training (2L:1R)
Number of subjects: 16
Study 12620717 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 anti-phase frequency-scaled coordination task
Number of subjects: 16
Study 10734696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (USG) for measuring femoral head and neck antetorsion angle
Number of subjects: 104
Study 10734696 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for increased antetorsion in children with spastic cerebral palsy
Number of subjects: 104
Study 10734696 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for Perthes disease
Number of subjects: 104
Study 10734696 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for congenital hip dysplasia
Number of subjects: 104
Study 10734696 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective osteotomy of femoral proximal end
Number of subjects: 104
Study 10734696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (USG) for assessment of femoral antetorsion
Number of subjects: 104
Study 7745068 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa/HMG/GH (18 IU on alternate days, total dose 72 IU)
Number of subjects: 14
Study 7745068 — intervention group
Group type: COMPARATOR
Intervention: GnRHa/HMG placebo
Number of subjects: 14
Study 7745068 — intervention group
Group type: COMPARATOR
Intervention: GnRHa/HMG placebo (previous cycles)
Number of subjects: 14
Study 2117857 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg/day for 60 days
Number of subjects: 307
Study 2117857 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 900 mg/day for 60 days
Number of subjects: 307
Study 2117857 — intervention group
Group type: COMPARATOR
Intervention: Benznidazole at conventional dosage regimens
Number of subjects: 307
Study 2117857 — intervention group
Group type: COMPARATOR
Intervention: Nifurtimox at conventional dosage regimens
Number of subjects: 307
Study 2117857 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 307
Study 2117857 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurans (conventional therapy)
Number of subjects: 307
Study 7250461 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflumidone
Number of subjects: 0
Study 7250461 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 7250461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7250461 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 0
Study 30423452 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplogroup B4
Number of subjects: 472
Study 30423452 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplogroup B5
Number of subjects: 472
Study 30423452 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplogroup D4b
Number of subjects: 472
Study 30423452 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplogroup F
Number of subjects: 472
Study 28869475 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Process Training‐II (APT‐II)
Number of subjects: 46
Study 28869475 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 46
Study 26490296 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 448
Study 26490296 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 448
Study 24361805 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pulmonary hypertension (PH) in patients with diastolic dysfunction grades 1, 2, and 3
Number of subjects: 392
Study 24361805 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpulmonary pressure gradient (TPG) >12 mm Hg in HF patients with PH
Number of subjects: 392
Study 24361805 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival rates in HF patients with PH
Number of subjects: 392
Study 23000083 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis group (Group I)
Number of subjects: 240
Study 23000083 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group II)
Number of subjects: 240
Study 19317815 — intervention group
Group type: EXPERIMENTAL
Intervention: HiMF training (HiMFT)
Number of subjects: 55
Study 19317815 — intervention group
Group type: EXPERIMENTAL
Intervention: LoMF training (LoMFT)
Number of subjects: 55
Study 19317815 — intervention group
Group type: COMPARATOR
Intervention: HiMF control (HiMFC)
Number of subjects: 55
Study 19317815 — intervention group
Group type: COMPARATOR
Intervention: LoMF control (LoMFC)
Number of subjects: 55
Study 17616788 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 mg calcium carbonate + 1400 IU cholecalciferol
Number of subjects: 122
Study 17616788 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 IU cholecalciferol)
Number of subjects: 122
Study 15056835 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ACEI + ARB)
Number of subjects: 106
Study 15056835 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (ACEI or ARB)
Number of subjects: 106
Study 12599448 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG polysaccharides nucleic acid (BCG-PSN) 0.5 mg intramuscular injection, quaque die alterna, for 18 times
Number of subjects: 60
Study 12599448 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG polysaccharides nucleic acid (BCG-PSN)
Number of subjects: 60
Study 10450777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic training program
Number of subjects: 627